Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Increase in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNSGet Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 12,400 shares, a growth of 134.0% from the December 31st total of 5,300 shares. Based on an average trading volume of 49,800 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their target price on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, January 13th.

Read Our Latest Research Report on Barinthus Biotherapeutics

Barinthus Biotherapeutics Price Performance

NASDAQ BRNS traded up $0.05 during midday trading on Wednesday, hitting $0.98. 12,161 shares of the company traded hands, compared to its average volume of 43,613. Barinthus Biotherapeutics has a 52 week low of $0.80 and a 52 week high of $4.16. The company’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.21. The company has a market cap of $39.22 million, a PE ratio of -0.65 and a beta of -0.81.

Barinthus Biotherapeutics (NASDAQ:BRNSGet Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same quarter in the previous year, the business earned ($0.37) EPS. On average, research analysts predict that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

About Barinthus Biotherapeutics

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

Featured Articles

Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.